CN114072390B - Rad51抑制剂 - Google Patents

Rad51抑制剂 Download PDF

Info

Publication number
CN114072390B
CN114072390B CN202080035279.0A CN202080035279A CN114072390B CN 114072390 B CN114072390 B CN 114072390B CN 202080035279 A CN202080035279 A CN 202080035279A CN 114072390 B CN114072390 B CN 114072390B
Authority
CN
China
Prior art keywords
compound
optionally substituted
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080035279.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114072390A (zh
Inventor
J－M·拉皮埃尔
C·C·麦科马斯
J·瓦卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Setell Therapy
Original Assignee
Setell Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Setell Therapy filed Critical Setell Therapy
Publication of CN114072390A publication Critical patent/CN114072390A/zh
Application granted granted Critical
Publication of CN114072390B publication Critical patent/CN114072390B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080035279.0A 2019-03-12 2020-03-12 Rad51抑制剂 Active CN114072390B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816998P 2019-03-12 2019-03-12
US62/816998 2019-03-12
PCT/US2020/022293 WO2020186006A1 (en) 2019-03-12 2020-03-12 Rad51 inhibitors

Publications (2)

Publication Number Publication Date
CN114072390A CN114072390A (zh) 2022-02-18
CN114072390B true CN114072390B (zh) 2024-06-11

Family

ID=72422797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035279.0A Active CN114072390B (zh) 2019-03-12 2020-03-12 Rad51抑制剂

Country Status (15)

Country Link
US (3) US11247988B2 (https=)
EP (1) EP3938358B1 (https=)
JP (1) JP7460649B2 (https=)
KR (1) KR20210127790A (https=)
CN (1) CN114072390B (https=)
AU (1) AU2020235089A1 (https=)
BR (1) BR112021017336A2 (https=)
CA (1) CA3132987A1 (https=)
IL (1) IL285889B2 (https=)
MX (1) MX2021010916A (https=)
PH (1) PH12021552147A1 (https=)
SG (1) SG11202109399SA (https=)
TW (1) TW202104198A (https=)
WO (1) WO2020186006A1 (https=)
ZA (1) ZA202106284B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111263756B (zh) 2017-07-11 2023-05-16 赛泰尔治疗公司 Rad51抑制剂
SG10202107087YA (en) 2017-09-11 2021-07-29 Cyteir Therapeutics Inc Rad51 inhibitors
PH12021552147A1 (en) 2019-03-12 2023-01-04 Cyteir Therapeutics Inc Rad51 inhibitors
PH12021552205A1 (en) 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
KR20220024857A (ko) 2019-06-21 2022-03-03 사이티어 테라퓨틱스, 인크. 췌장암의 치료를 위한 rad51 억제제의 사용 방법
WO2021164746A1 (zh) * 2020-02-19 2021-08-26 江苏先声药业有限公司 取代芳基类化合物
WO2023078271A1 (zh) * 2021-11-02 2023-05-11 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
WO2023185831A1 (zh) * 2022-03-29 2023-10-05 正大天晴药业集团股份有限公司 含有噻唑环的化合物
CN114736173B (zh) * 2022-05-24 2024-06-11 无锡捷化医药科技有限公司 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法
EP4574817A1 (en) * 2023-12-21 2025-06-25 LoQus23 Therapeutics Limited Inhibitory compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014315A1 (en) * 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
CN111542521A (zh) * 2017-09-11 2020-08-14 赛泰尔治疗公司 Rad51抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6230780A (ja) 1985-04-17 1987-02-09 Ss Pharmaceut Co Ltd １，７−ナフチリジン誘導体及びこれを含有する薬剤
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
CN107007597A (zh) 2012-05-31 2017-08-04 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
JP2017100949A (ja) 2014-04-01 2017-06-08 大日本住友製薬株式会社 ５員環ヘテロアリール誘導体
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016140971A1 (en) * 2015-03-02 2016-09-09 The Regents Of The University Of California Novel rad51 inhibitors and uses thereof
US10442817B2 (en) * 2015-06-04 2019-10-15 Drexel University Inhibitors of RAD52 recombination protein and methods using same
PH12021552147A1 (en) 2019-03-12 2023-01-04 Cyteir Therapeutics Inc Rad51 inhibitors
PH12021552205A1 (en) 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014315A1 (en) * 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
CN111542521A (zh) * 2017-09-11 2020-08-14 赛泰尔治疗公司 Rad51抑制剂

Also Published As

Publication number Publication date
BR112021017336A2 (pt) 2021-11-09
CA3132987A1 (en) 2020-09-17
JP2022525069A (ja) 2022-05-11
IL285889B2 (en) 2024-09-01
EP3938358A4 (en) 2022-12-21
US20240360120A1 (en) 2024-10-31
US20200291014A1 (en) 2020-09-17
KR20210127790A (ko) 2021-10-22
ZA202106284B (en) 2023-02-22
WO2020186006A1 (en) 2020-09-17
IL285889B1 (en) 2024-05-01
AU2020235089A1 (en) 2021-09-23
IL285889A (en) 2021-10-31
EP3938358A1 (en) 2022-01-19
US11247988B2 (en) 2022-02-15
PH12021552147A1 (en) 2023-01-04
JP7460649B2 (ja) 2024-04-02
US20220259198A1 (en) 2022-08-18
US11932636B2 (en) 2024-03-19
EP3938358B1 (en) 2024-10-02
SG11202109399SA (en) 2021-09-29
CN114072390A (zh) 2022-02-18
MX2021010916A (es) 2021-10-01
TW202104198A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
CN114072390B (zh) Rad51抑制剂
US11084812B2 (en) RAD51 inhibitors
JP7628090B2 (ja) 膵臓がんの治療にｒａｄ５１阻害剤を利用する方法
HK40086120A (en) Rad51 inhibitors
HK40025149B (en) Rad51 inhibitors
HK40025149A (en) Rad51 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant